TAK-981, a SUMOylation inhibitor, suppresses AML growth immune-independently

Acute myeloid leukemia (AML) generally has an unsatisfactory prognosis despite the recent introduction of new regimens, including targeted agents and antibodies. To find a new druggable pathway, we performed integrated bioinformatic pathway screening on large OHSU and MILE AML databases, discovered...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Han Sun, Kim, Bo-Reum, Dao, Thien T. P., Kim, Jin-Mo, Kim, Yoon-Ju, Son, Hyunsong, Jo, Sihyang, Kim, Doyeon, Kim, Jiwoo, Suh, Young Ju, Kim, Hee-Je, Cho, Byung-Sik, Park, Sunghyouk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Myeloid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338213/
https://www.ncbi.nlm.nih.gov/pubmed/36809797
http://dx.doi.org/10.1182/bloodadvances.2022007956

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338213/
https://www.ncbi.nlm.nih.gov/pubmed/36809797
http://dx.doi.org/10.1182/bloodadvances.2022007956

Ejemplares similares